Department of Otolaryngology and Head and Neck Surgery, Metaxas Cancer Hospital, Piraeus, Greece.
Eur Rev Med Pharmacol Sci. 2022 Dec;26(2 Suppl):38-48. doi: 10.26355/eurrev_202212_30481.
The objective of this study was to evaluate efficacy and safety of a Hypertonic Seawater Solution (2.3% NaCl) containing brown and blue-green Algae (HSS-A) in comparison to Isotonic Saline Solution (ISS) regarding the improvement of nasal breathing in patients that have undergone surgical correction of a deviated nasal septum and radiofrequency turbinate volume reduction.
A total of 101 individuals were enrolled in the study (HSS-A: 57; ISS: 44). Nasal breathing was evaluated using a Peak Nasal Inspiratory Flow (PNIF) measurement device at four timepoints: prior to surgical intervention (up to 30 days pre-surgery) and at the 2nd, 10th and 20th postoperative days. On the 20th postoperative day, patients also answered a Nasal Surgical Questionnaire (NSQ) evaluating breathing ability and overall satisfaction from the use of both nasal sprays.
No significant differences were observed in PNIF measurements between groups at different points. On the 20th postoperative day, NSQ analysis showed that ISS-treated patients had more frequently moderate nasal bleeding compared to the HSS-A group (85.7% vs. 14.3%, p=0.038). No other statistically significant differences were observed between groups. When NSQ parameters were evaluated in a binary mode, a trend for reduced crusting scores was seen in the HSS-A group (15.9% vs. 35.5% in ISS, p=0.053). No safety concerns were reported throughout the study.
In patients that have undergone surgical correction of a deviated nasal septum and radiofrequency turbinate volume reduction, PNIF values did not differ significantly in patients receiving HSS-A and ISS solutions. Nasal bleeding was more frequent in ISS patients versus HSS-A. Overall, both solutions provided symptomatic relief and use satisfaction in the absence of side effects.
本研究旨在评估高渗海水溶液(2.3%氯化钠)中含有褐藻和蓝绿藻(HSS-A)与等渗盐水溶液(ISS)在改善鼻中隔偏曲矫正术后和射频鼻甲体积缩小术后患者鼻腔通气方面的疗效和安全性。
共有 101 名患者入组本研究(HSS-A:57 例;ISS:44 例)。使用峰值鼻吸气流量(PNIF)测量仪在四个时间点评估鼻腔通气:手术干预前(术前 30 天内)和术后第 2、10 和 20 天。在术后第 20 天,患者还回答了鼻腔手术问卷(NSQ),评估了使用两种鼻腔喷雾剂的呼吸能力和总体满意度。
在不同时间点,两组之间的 PNIF 测量值无显著差异。在术后第 20 天,NSQ 分析显示,与 HSS-A 组相比,ISS 治疗组患者更频繁地出现中度鼻出血(85.7% vs. 14.3%,p=0.038)。组间未观察到其他有统计学意义的差异。当 NSQ 参数以二项模式进行评估时,HSS-A 组的结痂评分降低趋势更为明显(15.9% vs. ISS 组的 35.5%,p=0.053)。整个研究过程中均未报告安全性问题。
在接受鼻中隔偏曲矫正术和射频鼻甲体积缩小术的患者中,接受 HSS-A 和 ISS 溶液治疗的患者的 PNIF 值无显著差异。ISS 组患者的鼻出血更为频繁。总的来说,两种溶液在没有副作用的情况下均能提供症状缓解和使用满意度。